Botulinum toxin type A
Protein / enzyme biologic targets SNAP25, TGFB1, TRPV1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 31 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (7) | US (FDA) | Xeomin | — | 2011-07-20 – 2026-06-25 | fda.gov ↗ |
| Label expansions (14) | US (FDA) | BOTOX COSMETIC | — | 2000-12-21 – 2024-10-18 | fda.gov ↗ |
| Label expansion | US (FDA) | DAXXIFY | — | 2023-08-11 | fda.gov ↗ |
| Label expansions (7) | US (FDA) | DYSPORT | — | 2015-07-15 – 2023-01-12 | fda.gov ↗ |
| Approved | EU (EMA) | Nuceiva | — | 2019-09-27 | europa.eu ↗ |
| Approved | US (FDA) | BOTOX COSMETIC | — | 1991-12-09 | fda.gov ↗ |
Trials 645 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 018 trials | ||||||
| Phase 0 | NCT07640035 | Oct → Dec 2026 expected | bruxism | Bilecik Seyh Edebali University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06785844 | Jul 2025 → Sep 2030 expected | — | Shaare Zedek Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT05997043 | Aug 2023 → Jul 2024 | Parkinson disease, overactive bladder | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT06349733 | Mar → Oct 2023 | — | Qilu Hospital of Shandong University | Completed | No outcome recorded |
| Phase 0 | NCT06437912 | Mar → Oct 2023 | — | Dezhou Hospital Qilu Hospital of Shandong University | Completed | No outcome recorded |
| Phase 0 | NCT05485207 | Apr 2022 → Feb 2025 | interstitial cystitis | Stanford University | Unknown | No outcome recorded |
| Phase 0 | NCT05330078 | Mar 2022 → May 2023 | keloid | University of California, San Diego | Completed | No outcome recorded |
| Phase 0 | NCT04984317 | Feb 2022 → Dec 2026 | female stress incontinence | Northwell Health | Suspended | No outcome recorded |
| Phase 0 | NCT04939909 | Jul → Dec 2021 | benign essential blepharospasm | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 0 | NCT04715048 | Jan 2021 → May 2025 | — | University of Southern California | Unknown | No outcome recorded |
| Phase 0 | NCT04467450 | Jun → Nov 2020 | bursitis | Benha University | Unknown | No outcome recorded |
| Phase 0 | NCT05463822 | Jun 2019 → Sep 2021 | overactive bladder | Stanford University | Completed | No outcome recorded |
| Phase 0 | NCT03186547 | Jun 2017 → Jun 2018 | — | Cairo University | Unknown | No outcome recorded |
| Phase 0 | NCT03346252 | May 2017 → Mar 2021 | headache disorder | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 0 | NCT03103594 | Aug 2015 → Aug 2016 | urinary bladder disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 0 | NCT05324839 | Feb → Mar 2014 | salivary substance, Clostridium botulinum type | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT01520441 | Mar 2011 → Mar 2014 | benign prostatic hyperplasia, prostate cancer | The University of Texas Health Science Center, Houston | Withdrawn | No outcome recorded |
| Phase 0 | NCT00565201 | Oct 2007 → Dec 2009 | stroke disorder | Emory University | Completed | No outcome recorded |
| Phase 136 trials · 1 met primary · 1 missed | ||||||
| Phase 1 | NCT07756580 | Aug 2026 → Mar 2027 expected | — | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT07645456 | Oct 2025 → Apr 2026 | benign prostatic hyperplasia | Benha University | Completed | No outcome recorded |
| Phase 1 | NCT06778421 | Mar → Sep 2025 | — | Center for Advanced Facial Plastic Surgery | Completed | No outcome recorded |
| Phase 1 | NCT06834789 | Feb → Nov 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT06788158 | Sep 2024 → Jan 2025 overdue | plantar fasciitis | Mexican Social Security Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05923996 | Feb → Jun 2024 | skin disorder | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT04580238 | Dec 2023 → Jan 2025 | carotid artery dissection, cerebral sinovenous thrombosis, hemorrhagic stroke, migraine disorder +2 | University of Alberta | Withdrawn | No outcome recorded |
| Phase 1 | NCT05766683 | Mar → Jun 2023 overdue | — | Henry Ford Health System | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05784363 | Oct 2022 → Jun 2024 | — | Merz North America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05585398 | Oct 2022 → Feb 2023 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04970407 | Jul 2021 → Mar 2022 | — | Ipsen | Completed | Missed primary |
| Phase 1 | NCT04944953 | Jun → Sep 2021 | — | Hugel | Completed | No outcome recorded |
| Phase 1 | NCT04917731 | Jun 2021 → Jun 2023 | — | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04631588 | Nov 2020 → Nov 2021 | — | Allergan | Completed | No outcome recorded |
| Phase 1 | NCT04171258 | May 2020 → Apr 2021 | cervical dystonia | Hugel | Completed | No outcome recorded |
| Phase 1 | NCT04186442 | May 2020 → Apr 2021 | overactive bladder | Hugel | Completed | No outcome recorded |
| Phase 1 | NCT03236012 | Jan 2019 → Jan 2022 | isolated hyperchlorhidrosis | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT03069911 | Nov 2018 → May 2019 | Parkinson disease, depressive disorder | Johns Hopkins University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03547141 | Apr → Aug 2018 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT03647982 | Mar → Oct 2018 | anhidrosis, isolated hyperchlorhidrosis | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT03317717 | Oct 2017 → Jan 2018 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 1 | NCT02008136 | Mar 2016 → Aug 2018 | — | VA Connecticut Healthcare System | Unknown | No outcome recorded |
| Phase 1 | NCT02577185 | Nov 2015 → Jul 2016 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02584686 | Oct 2015 → May 2016 | vasculogenic impotence | Cairo University | Completed | Met primary |
| Phase 1 | NCT02782702 | Sep 2015 → Nov 2017 | Darier disease, Hailey-Hailey disease | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 1 | NCT03203174 | Jan 2015 → Aug 2016 | — | University of California, Davis | Completed | No outcome recorded |
| Phase 1 | NCT02202070 | Jan → Dec 2015 | bruxism, temporomandibular joint dysfunction syndrome | Washington University School of Medicine | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02403219 | May 2013 → Feb 2014 | dry eye syndrome | Instituto de Oftalmología Fundación Conde de Valenciana | Completed | No outcome recorded |
| Phase 1 | NCT01832194 | Mar 2013 → Apr 2014 | scrotal disorder | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 1 | NCT01352546 | Aug 2010 → Dec 2012 | vaginismus | Plastic Surgery Professional Association | Completed | No outcome recorded |
| Phase 1 | NCT00816517 | Jan 2009 → Jun 2015 | psoriasis | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT00515944 | Aug 2007 → Feb 2008 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00280280 | Feb 2006 → Feb 2009 | — | Vanderbilt University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00529386 | Jan 2006 → Sep 2009 | chronic pain syndrome, chronic prostatitis | Queen's University | Terminated | No outcome recorded |
| Phase 1 | NCT00279903 | Nov 2005 → Aug 2008 | osteoarthritis, knee | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00175604 | Aug 2004 → Feb 2008 | — | University of British Columbia | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/228 trials · 1 met primary · 2 missed | ||||||
| Phase 1/2 | NCT07796490 | Nov 2026 → Nov 2028 expected | prostate cancer | The Methodist Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06230146 | May 2024 → Jan 2026 | keloid | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05158166 | Oct 2023 → Mar 2025 | spasmodic dystonia, voice disorders | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/2 | NCT05512039 | May 2023 → Sep 2026 overdue | overactive bladder | Dartmouth-Hitchcock Medical Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03991299 | Apr 2021 → Feb 2022 | obesity disorder, type 2 diabetes mellitus | Vanderbilt University Medical Center | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04752774 | Apr 2021 → Mar 2029 expected | — | Ipsen | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04281095 | Nov 2019 → Apr 2020 | — | ATGC Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03922139 | Oct 2019 → Dec 2021 | compartment syndrome | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 1/2 | NCT03066635 | Apr 2017 → Sep 2019 | cluster headache syndrome | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 1/2 | NCT02674269 | Oct 2016 | overactive bladder | UroGen Pharma Ltd. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02662972 | May 2016 → Nov 2018 | headache disorder, trigeminal neuralgia | Norwegian University of Science and Technology | Completed | Missed primary |
| Phase 1/2 | NCT02639052 | Feb → Jul 2016 | — | Temple University | Completed | Mixed |
| Phase 1/2 | NCT02074163 | Jan → Jun 2016 | hemicrania continua | ASIS Corporation | Unknown | No outcome recorded |
| Phase 1/2 | NCT02074150 | Jan → Jun 2016 | focal dystonia, spastic monoplegia | li nguyen | Unknown | No outcome recorded |
| Phase 1/2 | NCT02074293 | Jan → Jun 2016 | cervical dystonia | li nguyen | Unknown | No outcome recorded |
| Phase 1/2 | NCT02247193 | Dec 2015 → Jan 2020 | cleft lip, cleft palate | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 1/2 | NCT02498769 | Sep 2015 → Sep 2017 | atrial fibrillation | Joseph Mathew, M.D. | Completed | Missed primary |
| Phase 1/2 | NCT02259075 | Feb 2015 → Mar 2016 | migraine disorder | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 1/2 | NCT01553201 | Jul 2014 → Jul 2018 | chronic pain syndrome, endometriosis, levator syndrome | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | Met primary |
| Phase 1/2 | NCT02019017 | Oct 2013 → Feb 2014 | cluster headache syndrome | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 1/2 | NCT01921270 | Aug 2013 → Feb 2017 | oromandibular dystonia | Emory University | Completed | No outcome recorded |
| Phase 1/2 | NCT01518257 | Jan 2012 → Jan 2013 | osteoarthritis | Allergan | Completed | No outcome recorded |
| Phase 1/2 | NCT00894517 | Aug 2009 → Jun 2012 | benign prostatic hyperplasia | Allergan | Completed | No outcome recorded |
| Phase 1/2 | NCT00770406 | Jan 2009 → Jun 2010 | overactive bladder | Glostrup University Hospital, Copenhagen | Unknown | No outcome recorded |
| Phase 1/2 | NCT00732680 | Dec 2008 → Nov 2009 | empty nose syndrome | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1/2 | NCT00479154 | May 2007 → Apr 2008 | restless legs syndrome | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 1/2 | NCT00583219 | Mar 2006 → May 2008 | overactive bladder | Mayo Clinic | Completed | Mixed |
| Phase 1/2 | NCT00178945 | Mar 2004 → Mar 2006 | cervical dystonia, myofascial pain syndrome | Vanderbilt University | Completed | No outcome recorded |
| Phase 2152 trials · 4 met primary · 21 missed | ||||||
| Phase 2 | NCT07489430 | Sep 2026 → Jun 2028 expected | benign essential blepharospasm | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2 | NCT07847541 | Aug → Dec 2026 expected | temporomandibular joint disorder | Riphah International University | Recruiting | No outcome recorded |
| Phase 2 | NCT07553065 | Jul 2026 → Sep 2027 expected | overactive bladder | Vensica Therapeutics Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07537855 | Jun 2026 → Jun 2028 expected | erectile dysfunction | Northwestern University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07399782 | Apr → Sep 2026 overdue | obstructive sleep apnea syndrome | Hospital Felicio Rocho | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07486830 | Feb → Dec 2026 expected | vulvodynia | Center for Vulvovaginal Disorders | Recruiting | No outcome recorded |
| Phase 2 | NCT07399860 | Feb 2026 → Jan 2027 expected | hemorrhoid | Lomonosov Moscow State University Medical Research and Educational Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07335367 | Jan → Aug 2026 | androgenetic alopecia | Nanfang Hospital, Southern Medical University | Completed | No outcome recorded |
| Phase 2 | NCT07834164 | Nov 2024 → Jun 2026 | erectile dysfunction | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 2 | NCT06530524 | Oct 2024 → Oct 2026 expected | head and neck cancer | Sir Mortimer B. Davis - Jewish General Hospital | Not yet recruiting | No outcome recorded |
| Show all 152 trials opens the full record — a long page | ||||||
| Phase 2/323 trials · 1 met primary · 1 missed | ||||||
| Phase 2/3 | NCT07863856 | Dec 2026 → Aug 2028 expected | androgenetic alopecia | Sherief Ayman Hussein Shaamash | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06902805 | Dec 2025 → May 2027 expected | osteoarthritis, hand | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06755099 | Jan 2025 → Aug 2026 overdue | sexual disorder | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06721520 | Dec 2024 → Dec 2027 expected | achalasia, dyskinesia of esophagus, esophageal cancer, functional gastric disease | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06583590 | Aug 2024 → Aug 2025 overdue | erectile dysfunction | Aswan University Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06851598 | Jul 2024 → Feb 2025 overdue | premature ejaculation | Abdallah Mohamed Abdallah Mohamed Elgendy | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04695600 | Aug 2023 → Aug 2027 expected | disorder of pharynx, dysphagia lusoria, retrograde cricopharyngeus dysfunction | All India Institute of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05878951 | Jul 2023 → Sep 2026 overdue | overactive bladder | Northwestern University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05367271 | Aug 2022 → Sep 2024 | plantar fasciitis | Western Institute for Veterans Research | Completed | No outcome recorded |
| Phase 2/3 | NCT05651256 | Mar 2021 | temporomandibular joint disorder | University of Salamanca | Completed | No outcome recorded |
| Phase 2/3 | NCT04277247 | Jan 2021 → Dec 2022 | Parkinson disease, dystonic disorder | University of Calgary | Unknown | No outcome recorded |
| Phase 2/3 | NCT04756882 | Nov 2020 → May 2021 | reactive cutaneous fibrous lesion | Alexandria University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04274608 | Jan 2020 → Jul 2021 | obesity disorder | Tan Tock Seng Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03187626 | Nov 2018 → Feb 2021 | osteoarthritis, hand | Assistance Publique - Hôpitaux de Paris | Completed | Met primary |
| Phase 2/3 | NCT03102762 | Jan 2017 → Jan 2019 | erectile dysfunction, sexual disorder | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT02886988 | Oct 2016 → Dec 2017 | — | Xijing Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03894748 | Dec 2011 → Aug 2012 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 2/3 | NCT00997815 | Dec 2009 → Dec 2010 | alopecia totalis, alopecia universalis | Siriraj Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02428881 | Nov 2009 → Jul 2012 | Fowler syndrome | University College, London | Completed | No outcome recorded |
| Phase 2/3 | NCT01566292 | Sep 2009 → Sep 2010 | benign prostatic hyperplasia | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 2/3 | NCT00479596 | Jan → May 2007 | overactive bladder | Urological Sciences Research Foundation | Unknown | No outcome recorded |
| Phase 2/3 | NCT00447876 | Jul 2005 → Jan 2009 | plantar fasciitis | Ipsen | Completed | Missed primary |
| Phase 2/3 | NCT00370734 | May 2005 → Feb 2007 | eye disorder | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3179 trials · 39 met primary · 12 missed | ||||||
| Phase 3 | NCT05698979 | Jan 2027 → Feb 2028 expected | Raynaud disease, thromboangiitis obliterans | University Hospital, Toulouse | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07470164 | Jan 2027 → Jan 2030 expected | esotropia | Jaeb Center for Health Research | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07822893 | Oct 2026 → Oct 2029 expected | Parkinson disease | University Hospital, Toulouse | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06995287 | Feb 2026 → Jun 2028 expected | chronic pain syndrome, primary dysmenorrhea | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07210463 | Oct 2025 → Oct 2026 expected | — | Merz Aesthetics GmbH | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07122193 | Aug 2025 → Jun 2026 overdue | — | Merz North America, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07018713 | Aug 2025 → Oct 2027 expected | migraine disorder | Merz Therapeutics GmbH | Recruiting | No outcome recorded |
| Phase 3 | NCT07018700 | Aug 2025 → Mar 2027 expected | migraine disorder | Merz Therapeutics GmbH | Recruiting | No outcome recorded |
| Phase 3 | NCT07013240 | Jul 2025 → Feb 2027 expected | — | University Hospital, Bordeaux | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06794866 | Jan 2025 → Apr 2026 | — | AbbVie | Completed | No outcome recorded |
| Show all 179 trials opens the full record — a long page | ||||||
| Phase 4116 trials · 8 met primary | ||||||
| Phase 4 | NCT07867379 | Oct → Dec 2026 expected | myofascial pain syndrome | Riyadh Elm University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07794891 | Sep 2026 → Jun 2027 expected | — | AbbVie | Recruiting | No outcome recorded |
| Phase 4 | NCT07295288 | Jul 2026 → Jun 2027 expected | cranial nerve neuropathy | Vanderbilt University Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07646886 | Jul 2026 → Jun 2027 expected | — | Peking University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05393921 | Jun 2026 → Jul 2027 | benign prostatic hyperplasia, overactive bladder | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT07803276 | Apr 2026 → Feb 2027 expected | paraplegia | Fluminense Federal University | Recruiting | No outcome recorded |
| Phase 4 | NCT07220382 | Nov 2025 → Dec 2027 expected | abdominal wall malformation, compartment syndrome | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07082972 | Sep 2025 → Sep 2026 overdue | myofascial pain syndrome | Istanbul University | Recruiting | No outcome recorded |
| Phase 4 | NCT06195241 | Feb 2025 → Mar 2027 expected | benign essential blepharospasm, facial spasm | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06783621 | Jan 2025 → Mar 2026 | — | AbbVie | Completed | No outcome recorded |
| Show all 116 trials opens the full record — a long page | ||||||
| Phase not applicable93 trials · 4 met primary · 5 missed | ||||||
| — | NCT07624877 | Oct 2026 | chronic pain syndrome, neuroma | Ukrainian Society of Regional Anesthesia and Pain Therapy | Completed | No outcome recorded |
| — | NCT07795463 | Aug → Oct 2026 expected | salivary substance, Clostridium botulinum type | Pham Ngoc Thach University of Medicine | Recruiting | No outcome recorded |
| — | NCT07666347 | Jun → Dec 2026 expected | osteoarthritis, knee | Tanta University | Recruiting | No outcome recorded |
| — | NCT07665528 | Jun → Sep 2026 overdue | ulcer of anus and rectum | Islamabad Medical and Dental College | Recruiting | No outcome recorded |
| — | NCT07626983 | May → Dec 2026 expected | chronic pain syndrome, nervous system injury, neuroma | Ukrainian Society of Regional Anesthesia and Pain Therapy | Not yet recruiting | No outcome recorded |
| — | NCT07535723 | Apr → Oct 2026 expected | migraine disorder | Beni-Suef University | Not yet recruiting | No outcome recorded |
| — | NCT07568314 | Mar → Jun 2026 overdue | ulcer of anus and rectum | Islamabad Medical and Dental College | Recruiting | No outcome recorded |
| — | NCT07431944 | Feb 2026 overdue | — | Charitable Organisation Charitable Fund Superhumans (Co Cf Superhumans) | Not yet recruiting | No outcome recorded |
| — | NCT07673471 | Feb → May 2026 | bruxism, odontoclasia | Biruni University | Completed | No outcome recorded |
| — | NCT07452510 | Jan → Apr 2026 | bruxism, masticatory muscles, hypertrophy of, parasomnia, sleep bruxism type, temporomandibular joint disorder | Recep Tayyip Erdogan University | Completed | No outcome recorded |
| — | NCT07473635 | Jan → Jul 2026 overdue | complex regional pain syndrome type 1, complex regional pain syndrome type 2 | Bo Biering-Soerensen | Recruiting | No outcome recorded |
| — | NCT07236632 | Dec 2025 → Dec 2026 expected | premature ejaculation | Benha University | Not yet recruiting | No outcome recorded |
| — | NCT07070817 | Dec 2025 → Dec 2026 | — | houyajing | Withdrawn | No outcome recorded |
| — | NCT07270042 | Dec 2025 → Sep 2026 overdue | masticatory muscles, hypertrophy of | Latakia University | Not yet recruiting | No outcome recorded |
| — | NCT07561580 | Nov 2025 → Jul 2026 overdue | isolated hyperchlorhidrosis | Latakia University | Recruiting | No outcome recorded |
| — | NCT07545200 | Sep 2025 → Feb 2026 | bruxism, masticatory muscles, hypertrophy of, myofascial pain syndrome | Kahramanmaras Sutcu Imam University | Completed | No outcome recorded |
| — | NCT06974617 | May → Oct 2025 overdue | migraine disorder | Cairo University | Recruiting | No outcome recorded |
| — | NCT07137234 | Mar 2025 → May 2026 overdue | cleft lip | Mansoura University | Recruiting | No outcome recorded |
| — | NCT05910983 | Jan → Nov 2025 | benign prostatic hyperplasia, bladder neck obstruction, overactive bladder | Menoufia University | Unknown | No outcome recorded |
| — | NCT07526870 | Jul → Nov 2024 | — | Instituto de Oftalmología Fundación Conde de Valenciana | Completed | No outcome recorded |
| — | NCT06470581 | Jul 2024 → Apr 2026 overdue | complex regional pain syndrome | Seoul National University | Not yet recruiting | No outcome recorded |
| — | NCT06840730 | Jun 2024 → Jan 2025 | temporomandibular joint dysfunction syndrome | Hacettepe University | Completed | No outcome recorded |
| — | NCT07076355 | May → Dec 2024 | — | Tanta University | Completed | No outcome recorded |
| — | NCT07549113 | Apr 2024 → May 2027 expected | — | State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital | Recruiting | No outcome recorded |
| — | NCT06328556 | Mar → Dec 2024 | achalasia | Copka Sonpashan | Unknown | No outcome recorded |
| — | NCT07385742 | Jan 2024 → Mar 2025 | temporomandibular joint disorder | Suez Canal University | Completed | No outcome recorded |
| — | NCT06218316 | Oct 2023 → Jan 2024 | spastic diplegia | MTI University | Completed | No outcome recorded |
| — | NCT05604729 | Sep 2023 → Dec 2024 | bruxism, tooth erosion, non-bacterial | Region Västerbotten | Unknown | No outcome recorded |
| — | NCT06345677 | Jun 2023 → Feb 2024 | overactive bladder | Vensica Therapeutics Ltd. | Completed | No outcome recorded |
| — | NCT04220931 | Mar 2023 → Dec 2026 expected | pancreas disorder | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| — | NCT06179082 | Feb → Oct 2023 | — | Zagazig University | Completed | No outcome recorded |
| — | NCT05863286 | Dec 2022 → Dec 2023 | temporomandibular joint disorder | Cairo University | Unknown | No outcome recorded |
| — | NCT06196606 | Nov 2022 → Dec 2024 | brain stem infarction, esophageal disorder | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| — | NCT06213662 | Nov 2022 → Jul 2024 | achalasia | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| — | NCT05382832 | Aug 2022 | migraine disorder | EPC Education s.r.o. | Unknown | No outcome recorded |
| — | NCT06122545 | May 2022 → May 2024 | migraine disorder | Tanta University | Unknown | No outcome recorded |
| — | NCT06282679 | Apr 2022 → Mar 2024 | rosacea, salivary substance, Clostridium botulinum type | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT05911594 | Feb 2022 → Feb 2023 | — | Benha University | Completed | No outcome recorded |
| — | NCT05194488 | Jan → May 2022 | temporomandibular joint dysfunction syndrome | Nourhan M.Aly | Completed | No outcome recorded |
| — | NCT05517538 | Aug → Dec 2021 | — | Mohamed Hayder Oleish Salih | Completed | No outcome recorded |
| — | NCT05620316 | Mar → Sep 2021 | parasomnia, sleep bruxism type | Damascus University | Completed | No outcome recorded |
| — | NCT04383912 | Nov 2020 → Jul 2024 | Tented eyebrows | Nova Scotia Health Authority | Unknown | No outcome recorded |
| — | NCT04270214 | Jun 2020 → Oct 2022 | cervical dystonia | Western University, Canada | Unknown | No outcome recorded |
| — | NCT05309564 | Mar 2020 → Jan 2022 | salivary substance, Clostridium botulinum type | Region Västerbotten | Completed | No outcome recorded |
| — | NCT04290169 | Feb 2020 → Mar 2022 | spastic cerebral palsy | Sunnaas Rehabilitation Hospital | Unknown | No outcome recorded |
| — | NCT03891680 | Oct 2019 → Mar 2020 | osteoarthritis, knee | Assiut University | Completed | No outcome recorded |
| — | NCT04366869 | Jul 2019 → Jul 2020 | bruxism | October University for Modern Sciences and Arts | Completed | No outcome recorded |
| — | NCT03284047 | Apr 2019 | gingival disorder | Northwestern University | Withdrawn | No outcome recorded |
| — | NCT04940104 | Jan → Jun 2019 | bruxism | British University In Egypt | Completed | No outcome recorded |
| — | NCT04544280 | Sep 2018 → Dec 2021 | stroke disorder | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | Met primary |
| — | NCT03891121 | Apr 2018 → Feb 2019 | myofascial pain syndrome, temporomandibular joint disorder | Ankara University | Completed | No outcome recorded |
| — | NCT03484754 | Apr 2018 → Jul 2021 | major depressive disorder | Centre Hospitalier Esquirol | Unknown | Met primary |
| — | NCT03747900 | Oct 2017 → Mar 2018 | — | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | Completed | No outcome recorded |
| — | NCT03306940 | Oct 2017 → Jul 2018 | facial spasm | Tongji University | Unknown | No outcome recorded |
| — | NCT03131791 | Apr → Jul 2017 | diplegia of upper limb | Mackay Memorial Hospital | Completed | Met primary |
| — | NCT03704155 | Jan 2017 → May 2018 | spastic cerebral palsy | University of Nove de Julho | Completed | No outcome recorded |
| — | NCT02917967 | Nov 2016 → Sep 2018 | cerebral palsy | Yonsei University | Completed | No outcome recorded |
| — | NCT02909907 | Aug 2016 → Feb 2018 | essential tremor | The Cleveland Clinic | Completed | No outcome recorded |
| — | NCT02351544 | Sep 2015 → Jun 2022 | migraine disorder | Ohio State University | Completed | No outcome recorded |
| — | NCT02369068 | Aug 2015 → Mar 2018 | pelvis syndrome | Jamie Bartley, DO | Completed | Missed primary |
| — | NCT02444351 | Jun 2015 → Jun 2016 | spinal stenosis | Yonsei University | Completed | No outcome recorded |
| — | NCT02187679 | Jan 2014 → Jun 2017 | Tourette syndrome, chronic tic disorder | Detroit Clinical Research Center | Unknown | No outcome recorded |
| — | NCT01859507 | Jan 2013 → Mar 2014 | vaginismus | Abdel-Maguid Ramzy | Completed | No outcome recorded |
| — | NCT01635504 | Oct 2012 → Jan 2015 | AIDS dysmorphic syndrome | University of British Columbia | Completed | No outcome recorded |
| — | NCT01829087 | Aug 2012 → Aug 2014 | — | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| — | NCT01483209 | Mar 2012 → Apr 2014 | ischemic disease | Duke University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01803464 | Mar 2012 → Feb 2015 | cerebral palsy | University of Delaware | Completed | No outcome recorded |
| — | NCT01274611 | Dec 2010 → Dec 2011 | isolated hyperchlorhidrosis | Northwestern University | Completed | No outcome recorded |
| — | NCT01225341 | Aug 2010 → May 2012 | herpes labialis | DeNova Research | Terminated | No outcome recorded |
| — | NCT01760577 | May 2010 → May 2012 | osteoarthritis | Kaohsiung Veterans General Hospital. | Completed | Missed primary |
| — | NCT00999869 | Nov 2009 → Dec 2012 | alopecia areata | Siriraj Hospital | Unknown | No outcome recorded |
| — | NCT06899438 | Aug 2009 → Jan 2010 | myofascial pain syndrome | Bursa City Hospital | Completed | No outcome recorded |
| — | NCT00822523 | Jan → Mar 2009 | salivary substance, Clostridium botulinum type | Loma Linda University | Completed | Missed primary |
| — | NCT00822926 | Jan 2009 → Dec 2013 | — | Stanford University | Terminated | No outcome recorded |
| — | NCT00900666 | Jan 2009 → Jun 2011 | brain injury | Mary Free Bed Rehabilitation Hospital | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00725322 | Dec 2007 → Mar 2013 | — | Stanford University | Completed | No outcome recorded |
| — | NCT00408798 | Oct 2007 → Oct 2009 | alopecia areata | University of British Columbia | Completed | No outcome recorded |
| — | NCT00435682 | Mar 2007 → Jan 2008 | — | Aalborg University | Completed | No outcome recorded |
| — | NCT00395616 | Nov 2006 → ? | epicondylitis, salivary substance, Clostridium botulinum type | E-DA Hospital | Unknown | No outcome recorded |
| — | NCT00336349 | Jun 2006 → Dec 2007 | diabetes mellitus, neuropathy, painful | Taipei Medical University Hospital | Completed | No outcome recorded |
| — | NCT01590693 | Nov 2005 → Jan 2012 | — | Karolinska Institutet | Completed | Missed primary |
| — | NCT00345332 | Oct 2005 → May 2011 | — | University of Rochester | Completed | Met primary |
| — | NCT00152334 | Sep 2005 → Mar 2016 | clubfoot | University of British Columbia | Completed | No outcome recorded |
| — | NCT00152347 | Sep 2005 → Sep 2015 | clubfoot | University of British Columbia | Completed | No outcome recorded |
| — | NCT00250952 | Feb → Jun 2005 | skin atrophy | Carruthers Dermatology Centre | Completed | No outcome recorded |
| — | NCT00850421 | Apr 2004 → Apr 2010 | migraine disorder | HealthPartners Institute | Terminated | No outcome recorded |
| — | NCT01129583 | Nov 2003 → Sep 2009 | — | Columbia University | Completed | Missed primary |
| — | NCT00661089 | Sep 2003 → Mar 2009 | — | Shirley Ryan AbilityLab | Completed | Mixed |
| — | NCT00173745 | Jun 2003 → Sep 2005 | cerebral palsy | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT00474032 | Mar 2003 → Mar 2023 | clubfoot | University of British Columbia | Unknown | No outcome recorded |
| — | NCT00282958 | Feb 2003 → Jul 2006 | — | Palo Alto Veterans Institute for Research | Completed | No outcome recorded |
| — | NCT00004480 | Jul 1999 → ? | isolated hyperchlorhidrosis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| — | NCT00004416 | Jan 1997 → Mar 2002 | achalasia | University of Texas | Completed | No outcome recorded |
| Comparator or background therapy267 trials | ||||||
| Phase 0 | NCT05807412 Comparator | May 2023 → Feb 2024 | — | Lupo Center for Aesthetic and General Dermatology | Completed | No outcome recorded |
| Phase 0 | NCT05305768 Comparator | May 2022 → Feb 2023 | — | Clinical Testing of Beverly Hills | Unknown | No outcome recorded |
| Phase 0 | NCT05083286 Comparator | Oct 2021 → Aug 2022 | — | Clinical Testing of Beverly Hills | Unknown | No outcome recorded |
| Phase 0 | NCT03616262 Comparator | Jul 2016 → Dec 2019 | complex regional pain syndrome | VA Connecticut Healthcare System | Unknown | No outcome recorded |
| Phase 0 | NCT02524236 Comparator | Aug 2015 → Nov 2016 | benign prostatic hyperplasia | Beni-Suef University | Completed | No outcome recorded |
| Show all 267 trials opens the full record — a long page | ||||||
Press releases naming this drug 199 releases
Evidence & citations 112 cited values
Every value below carries the sentence it was read from. 984 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | botulinum toxin type A | “Since its introduction in the 1970s for the treatment of strabismus, blepharospasm, and focal dystonia, botulinum toxin type A (BTX-A) has been widely used in the treatment of...” NCT03555916 ↗341“Another recent evidence suggests an enhanced sensitization of central pain processing in patients with RLS. This had led to consider the botulinum toxin type A (BNT) as an...” NCT00949806 ↗ “The SILENCE-NEUROMA Trial is a multicenter, randomized, double-blind, active-controlled study designed to compare the efficacy and safety of botulinum toxin type A versus local...” NCT07431944 ↗ “The safety and efficacy of Mentor Purified Toxin, Botulinum Toxin Type A, Purified Neurotoxin, injected intramuscularly into the neck, is being evaluated as a treatment for...” NCT00549341 ↗ “Botulinum toxin type A (BoNT-A), a peripheral neuromodulator, has been proposed as a potential therapeutic alternative by inducing chemodenervation and muscle volume reduction,...” NCT07399782 ↗ “The main objective is to evaluate the analgesic efficacy of botulinum toxin type A in refractory chronic proctalgia one month after a bilateral injection of 50 units of Botox ®...” NCT01331356 ↗ “In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial;...” NCT03920449 ↗ “Botox containing Botulinum toxin type A is a purified substance, derived from a bacterium that block muscular nerve signals temporarily preventing the muscular contraction and...” NCT05162300 ↗ “Botulinum toxin type A (BTX-A; Botox, Allergan, Inc., Irvine, CA, USA) was administered through intramuscular injection into the masseter and temporalis muscles during a single...” NCT07361900 ↗ “The aim was to compare the efficacy of intraarticular Botulinum toxin type A (BoNT-A) and intraarticular hyaluronate plus rehabilitation exercise in patients with ankle OA.” PMID 24502534 ↗ Feb 2014 “Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)” NCT03779841 ↗ |
| Known as | 25 units botox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06851598 ↗ |
| Known as | 93094EC | “Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC” NCT04383912 ↗ |
| Known as | ABO | “Drug: AbobotulinumtoxinA (ABO)” NCT01732809 ↗ |
| Known as | aboBoNT-A | “AIM: To define optimal (safe and efficacious) doses of abobotulinumtoxinA (aboBoNT-A) for the treatment of PVD associated with hypertonic pelvic floor muscle dysfunction and to...” PMID 39953376 ↗ Apr 20253“OBJECTIVE: To assess changes in walking velocity (WV), step length, and cadence under different test conditions after repeated treatment with abobotulinumtoxinA (aboBoNT-A;...” PMID 32741133 ↗ Sep 2020 “Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations.” PMID 37205243 ↗ Mar 2023 “OBJECTIVE: To assess the efficacy and safety of abobotulinumtoxinA (aboBoNT-A) for NDOI.” PMID 35400537 ↗ Apr 2022 |
| Known as | Abobotulinum Toxin A | “The most commonly used subtype is toxin A commercially found as BOTOX (onabotulinumtoxinA, Allergan, approved by FDA in 1989), Dysport (abobotulinumtoxinA, Medicis, approved by...” NCT03186001 ↗49“In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation...” NCT05874154 ↗ “AIM: To define optimal (safe and efficacious) doses of abobotulinumtoxinA (aboBoNT-A) for the treatment of PVD associated with hypertonic pelvic floor muscle dysfunction and to...” PMID 39953376 ↗ Apr 2025 “This study aims to evaluate the efficacy of single event multi level chemoneurolysis with the abobotulinumtoxin A drug, Dysport®, on walking energy expenditure and gait in...” NCT03469999 ↗ “OBJECTIVE: To assess changes in walking velocity (WV), step length, and cadence under different test conditions after repeated treatment with abobotulinumtoxinA (aboBoNT-A;...” PMID 32741133 ↗ Sep 2020 “In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial;...” NCT03920449 ↗ “Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations.” PMID 37205243 ↗ Mar 2023 “The ONTIME study investigated whether early post-stroke abobotulinumtoxinA injection delays appearance or progression of upper limb spasticity (ULS) symptoms.” PMID 29933562 ↗ Jun 2018 “Their study designs involved repeat intramuscular injections of abobotulinumtoxinA (Dysport®), and efficacy endpoints were collected accordingly.” PMID 29781237 ↗ May 2018 “different doses of botulinum toxin type A (abobotulinumtoxin A) for the treatment of upper anterior gummy smile” NCT03284047 ↗ “AbobotulinumtoxinA solution for injection is a ready-to-use liquid formulation of abobotulinumtoxinA.” PMID 27653448 ↗ Sep 2016 |
| Known as | AbobotulinumtoxinA (Azzalure) | “AbobotulinumtoxinA (Azzalure®)” NCT01333397 ↗ |
| Known as | AbobotulinumtoxinA (Dysport) | “AbobotulinumtoxinA (Dysport®)” NCT02106351 ↗15“AbobotulinumtoxinA (Dysport®)” NCT03598777 ↗ “AbobotulinumtoxinA (Dysport®)” NCT03569098 ↗ “AbobotulinumtoxinA (Dysport®)” NCT01261611 ↗ “AbobotulinumtoxinA (Dysport®)” NCT00455637 ↗ “AbobotulinumtoxinA (Dysport®)” NCT02321436 ↗ “AbobotulinumtoxinA (Dysport®)” NCT00210444 ↗ “AbobotulinumtoxinA (Dysport®)” NCT00257660 ↗ “AbobotulinumtoxinA (Dysport®)” NCT01251367 ↗ “abobotulinumtoxinA (Dysport®)” NCT04970407 ↗ “AbobotulinumtoxinA (Dysport®)” NCT00234507 ↗ |
| Known as | AbobotulinumtoxinA (DysportRU) | “AbobotulinumtoxinA (DysportRU®)” NCT01261611 ↗1“AbobotulinumtoxinA (DysportRU®)” NCT01333397 ↗ |
| Known as | aboboutlinum toxin A | “This prospective double-blind randomized control trial seeks to compare a single formulation of BoNT, aboboutlinum toxin A (Dysport), to a placebo saline group, studying the...” NCT03639766 ↗ |
| Known as | ABoNT/A | “1 dose of 60 units of abobotulinum toxin A (ABoNT/A);” PMID 40434770 ↗ Jul 2025 |
| Known as | AGN 151607 | “Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)” NCT03779841 ↗ |
| Known as | ANT-1207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02479139 ↗ |
| Known as | ANT-1401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01951742 ↗ |
| Known as | ANT-1403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01799824 ↗ |
| Known as | Azzalure | “Botulinum Toxin Type A (Azzalure)” NCT01529203 ↗ |
| Known as | Bao Tuo Shi | “Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)” NCT05380154 ↗ |
| Known as | BNT | “Recently, botulinum toxin type A (BNT) has been reported to relief RLS in patients with severe symptoms but this was not confirmed by other anecdotal reports.” NCT00949806 ↗ |
| Known as | Bocouture | “IncobotulinumtoxinA (NT 201,
Xeomin/Xeomeen/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany) is a
150-kDa botulinum toxin type A free of complexing proteins.” PMID 23379292 ↗ Feb 20131“NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton).” NCT00777803 ↗ |
| Known as | BoNT | “Onabotulinumtoxin A (BoNT)” NCT02600715 ↗ |
| Known as | BoNT A1 = Dysport | “BoNT A1 = Dysport” NCT00959907 ↗ |
| Known as | BoNT A2 = Botox | “BoNT A2 = Botox” NCT00959907 ↗ |
| Known as | BoNT-A | “Although numerous articles were published on the Botulinum Toxin A (BoNTA) injection in the management of MPS, but there were diverse clinical results in the literature...” NCT06824324 ↗35“Botulinum toxin type A (BoNT-A), a peripheral neuromodulator, has been proposed as a potential therapeutic alternative by inducing chemodenervation and muscle volume reduction,...” NCT07399782 ↗ “Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic...” NCT03704155 ↗ “Participants with a Modified Ashworth Scale (MAS) score of 1+ or above received BoNT-A (Dysport) 500 U or placebo to one or more wrist and elbow mover muscles, plus...” PMID 22371239 ↗ Feb 2012 “OBJECTIVE: To investigate whether extracorporeal shock wave therapy (ESWT) is noninferior to botulinum toxin type A (BoNT-A) for the treatment of poststroke upper limb spasticity.” PMID 30392753 ↗ Jul 2018 “Botulinum Neurotoxin-A (BoNT-A), when applied intramuscularly, inhibits presynaptic acetylcholine (Ach) release by preventing the fusion of Ach vesicles with the plasma membrane.” NCT06583343 ↗ “The aim was to compare the efficacy of intraarticular Botulinum toxin type A (BoNT-A) and intraarticular hyaluronate plus rehabilitation exercise in patients with ankle OA.” PMID 24502534 ↗ Feb 2014 “Botulinum toxin type-A (BoNT-A) is often used for refractory cases unresponsive to conservative therapies; however, its biological mechanisms remain unclear.” PMID 42062988 ↗ Apr 2026 “OBJECTIVE: To assess the efficacy of intradermally injected botulinum neurotoxin type A (BoNT/A) in patients with Restless Legs Syndrome (RLS).” PMID 23063302 ↗ Oct 2012 “Botulinum toxin A (BoNT-A) injection is one of the most widely used methods for hemifacial spasm (HFS) with high efficacy in controlling spasm.” PMID 27431279 ↗ Jul 2016 “Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.” NCT06203470 ↗ |
| Known as | BoNT-A (BOTOX 300U) | “BoNT-A (BOTOX 300U)” NCT01682603 ↗ |
| Known as | BoTN | “STUDY QUESTION: Does the depth of injection of onabotulinumtoxinA neurotoxin in the glabellar complex affect efficacy of the BoTN for the improvement of glabellar frown lines?” NCT05766683 ↗ |
| Known as | BoTN/A | “Observational data suggest that intrapyloric injection of botulinum toxin A (BoTN/A) reduces symptoms and accelerates gastric emptying in idiopathic and diabetic gastroparesis.” PMID 18070232 ↗ Dec 2007 |
| Known as | Botox | “Each patient will receive (either in the lower part or the upper part of the scar according to randomization) 50 international units (IU) of type A botulinum toxin (Botox®,...” NCT07013240 ↗240“The primary objective of this study is to determine whether intramuscular injections of botulinum toxin type A (Botox®) in selected cervical muscles at antidystonic dosages can...” NCT00477802 ↗ “Patients were randomly assigned (1:1) by a central web form to receive intrarectal submucosal injections of either 200 units of BoNTA (Botox; Allergan, Irvine, CA, USA; BoNTA...” PMID 38128556 ↗ Dec 2023 “Treatment consisted of a multimodal approach including intravaginal injections of onabotulinumtoxinA (Botox) and bupivacaine, progressive dilation under conscious sedation,...” PMID 28363809 ↗ Mar 2017 “This pilot randomized, single-blind, placebo-controlled study evaluates the feasibility, safety, and preliminary biological activity of neoadjuvant intraprostatic...” NCT07796490 ↗ “This is a randomised, double-blind, intra-individual controlled, dose escalation study to assess the safety, tolerability and preliminary effectiveness of a single dose of...” NCT03796351 ↗ “The botulinum toxin (BOTOX®), which can exert a paralytic effect by binding to presynaptic cholinergic nerve terminals at the neuromuscular junction, is produced by the...” NCT06974617 ↗ “The current study will investigate the comparative efficacy, safety and patient satisfaction of intradetrusor injections BOTOX® injections (200U) versus placebo (saline)...” NCT00479596 ↗ “The BTX-A group will receive onabotulinumtoxinA (Botox®, Allergan) with mandatory muscles getting 300 units and optional muscles getting up to 100 additional units (maximum...” NCT06296082 ↗ “Multicenter, Double-blind, Randomized, Parallel Design, Active-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of 100 Units of BMI 2006 and Botox® in...” NCT05531968 ↗ “A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified...” NCT03915067 ↗ |
| Known as | Botox (onabotulinumtoxinA)injection | “Botox® (onabotulinumtoxinA)injection” NCT00950664 ↗ |
| Known as | Botox , "Allergan" | “Botox ®, "Allergan"” NCT01698138 ↗1“Botox (Allergan)” NCT01589471 ↗ |
| Known as | Botox A | “We present the rationale for and design of a randomized, open-label, active-control trial comparing the effectiveness of 200 units of onabotulinum toxin A (Botox A®) versus...” PMID 24486637 ↗ Jan 20143“Botulinum toxin-A (Botox-A) is used as pharmacologic agent not only for aesthetic purposes, but also for its vasomotor actions.” PMID 27997734 ↗ Jan 2017 “Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC” NCT04383912 ↗ “intralesional Botox-A (100 U vacuum-dried powder in a single-use vial” NCT06230146 ↗ |
| Known as | Botox Cosmetic | “onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.” NCT02176356 ↗4“Subjects will be given the same-day combination of VI Peel (Procedure) and Botox Cosmetic (Botulinum Toxin) (Drug).” NCT05162300 ↗ “Botox® Cosmetic (Allergan, Irvine, CA), is the first FDA-approved Botulinum toxin type A” NCT01529788 ↗ “Hyper-Diluted OnabotulinumtoxinA (Botox®, Botox® Cosmetic /BTXa/)” NCT03097835 ↗ “1. BOTOX Cosmetic (onabotulinumtoxinA) for Injection” NCT01269801 ↗ |
| Known as | Botox Inj. | “To compare the safety and efficacy of Botulax Inj.®(Botulinum toxin type A, Hugel, South Korea) with Botox Inj.® (Botulinum toxin type A, Allergan, USA) in the treatment of...” NCT01787344 ↗1“Botox Inj(Clostridium botulinum type A)” NCT04081402 ↗ |
| Known as | BOTOX OnabotulinumtoxinA | “Botox (onabotulinumtoxinA)” NCT02074150 ↗3“Botox (onabotulinumtoxinA)” NCT02074163 ↗ “Botox (onabotulinumtoxinA)” NCT02074293 ↗ “BOTOX® OnabotulinumtoxinA” NCT01603615 ↗ |
| Known as | BOTOX(c) | “The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard...” NCT05512039 ↗ |
| Known as | Botulax | “Biological: Botulinum toxin type A(Botulax®)” NCT01915459 ↗ |
| Known as | Botulax Inj. | “To compare the safety and efficacy of Botulax Inj.®(Botulinum toxin type A, Hugel, South Korea) with Botox Inj.® (Botulinum toxin type A, Allergan, USA) in the treatment of...” NCT01787344 ↗ |
| Known as | Botulift | “botulinum toxin Botulift® (botulinum toxin type A)” NCT03812965 ↗ |
| Known as | Botulinum A Toxin | “Botulinum-A toxin is a selective blocker of acetylcholine release from nerve endings and inhibits neural transmission when injected into muscle” NCT06851598 ↗7“Botulinum A Toxin (Botox) Injection in the Gastrocnemius Muscle in Children With Idiopathic Toe Walking” NCT00175669 ↗ “A multi-center clinical trial of Botulinum-A Toxin (Botox) for refractory urge incontinence.” NCT00345332 ↗ |
| Known as | Botulinum Neurotoxin Type A | “OBJECTIVE: To assess the efficacy of intradermally injected botulinum neurotoxin type A (BoNT/A) in patients with Restless Legs Syndrome (RLS).” PMID 23063302 ↗ Oct 20121“Clinical Trial To Evaluate Botulinum Neurotoxin Type A (ANT-1207) In Subjects With Acne” NCT01293552 ↗ |
| Known as | botulinum neurotoxin-A | “Botulinum Neurotoxin-A (BoNT-A), when applied intramuscularly, inhibits presynaptic acetylcholine (Ach) release by preventing the fusion of Ach vesicles with the plasma membrane.” NCT06583343 ↗2“Encouraging results were reported with the use of botulinum neurotoxin-A (BoNT-A).” PMID 26808752 ↗ Sep 2016 “Comparison of Two Botulinum Neurotoxin A Injection Patterns” PMID 26885381 ↗ Jan 2016 |
| Known as | Botulinum toxin | “Botulinum toxin or Botox, as it is commonly called, has the potential to temporarily reduce the tension in the muscles without causing permanent damage.” NCT00624299 ↗6“This study examines botulinum toxin (BOTOX, or BTX) for the treatment of muscle twitches and spasticity associated with cerebral palsy in children.” NCT00060957 ↗ “botulinum toxin (BoNT-A) interventions prospectively compared to find out the effect of BoNT-A injection on myofascial pain syndrome (MPS).” NCT06899438 ↗ “intramuscular injection of 100U botulinum toxin (BoNT-A) is a reasonable choice for the treatment of bladder overactivity in PD” NCT05997043 ↗ “Subjects will be given the same-day combination of VI Peel (Procedure) and Botox Cosmetic (Botulinum Toxin) (Drug).” NCT05162300 ↗ “As an alternative to strabismus surgery, botulinum toxin (Botox) can be applied in extraocular muscles.” NCT03459092 ↗ “Botox (botulinum toxin)” NCT01412008 ↗ |
| Known as | Botulinum toxin (BTX) A | “50 units of Botulinum toxin (BTX) A” NCT02584686 ↗ |
| Known as | Botulinum Toxin A | “The hypothesis is that therapeutic treatment of drooling in children with cerebral palsy consisting of a standardized rehabilitation treatment associated with a botulinum toxin...” NCT03616067 ↗148“This is a 12-week, prospective double-blinded, randomized, multicenter study of placebo, 120 Unit, and 240 unit of botulinum toxin A ( Dysport ® ) injection for patient with a...” NCT00258609 ↗ “This study aims to assess whether or not a single injection schedule of botulinum toxin A (BTX-A) in both hands improves Raynaud phenomenon (RP) secondary to systemic sclerosis...” NCT03717961 ↗ “The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic...” NCT02674269 ↗ “This is a randomized, double-blinded, clinical trial assessing the therapeutic efficacy of Botulinum toxin A (Onabotulinumtoxin A) in treating scleroderma-associated Raynaud's syndrome.” NCT02165111 ↗ “Improvement in skin lesions after botulinum toxin A injections has previously been reported in some patients but no prospective interventional studies are available.” PMID 33602313 ↗ Feb 2021 “Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.” NCT01905137 ↗ “Botulinum toxin A is widely used to alleviate facial dynamic rhytides but is also believed to improve scar quality by reducing wound tension during healing.” PMID 25541942 ↗ Dec 2014 “Between 2004 and 2015, a total of 145 patients underwent botulinum toxin-A (BTX-A) injections to treat RP in case reports, retrospective or open studies.” NCT03717961 ↗ “injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.” NCT04220931 ↗ “Botulinum toxin A and placed will be injected near the neurovascular bundle at the A1 pulley in the palm of the hand using a total dosage 100 U per hand” NCT06460194 ↗ |
| Known as | Botulinum Toxin A (BoNT-A) | “Botulinum Toxin A (BoNT-A)” NCT01733290 ↗ |
| Known as | Botulinum toxin type A (150 kD), free from complexing proteins | “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins'” NCT00430963 ↗ |
| Known as | Botulinum toxin type A (150 kiloDalton), free from complexing proteins | “IncobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT01515371 ↗3“NT 201 (Xeomin®, also know as IncobotulinumtoxinA or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT00541905 ↗ “IncobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins")” NCT01603459 ↗ “incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins")” NCT00432666 ↗ |
| Known as | Botulinum toxin type A (150kD), free of complexing proteins | “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:” NCT00541723 ↗ |
| Known as | Botulinum toxin type A (Botox) | “Botulinum toxin type A (Botox)” NCT00908050 ↗ |
| Known as | botulinum toxin type A [150 kDa] | “incobotulinumtoxinA (also known as botulinum toxin type A [150 kDa], free from complexing proteins, or previously as NT 201)” PMID 22010053 ↗ Oct 2011 |
| Known as | Botulinum toxin type A for injection (Hengli National Drug approval number S10970037) | “Botulinum toxin type A for injection (Hengli National Drug approval number S10970037)” NCT06213662 ↗1“Botulinum toxin type A for injection (Hengli National Drug approval number S10970037)” NCT06196606 ↗ |
| Known as | Botulinum Toxn Type A | “Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin” NCT00549341 ↗ |
| Known as | Botulinum Type A | “Drug: Botulinum Type A” NCT01429402 ↗ |
| Known as | BTA | “The main objective of this prospective, open, uncontrolled pilot study was to investigate the safety of administering onabotulinumtoxinA (BTA) towards the sphenopalatine...” PMID 34633904 ↗ Oct 202114“Forty patients with stroke with spasticity in a functionally useless arm (median duration 3.1 years) were randomised to receive intramuscular botulinum toxin type A (BT-A;...” PMID 10896696 ↗ Aug 2000 “To investigate the efficacy and safety of injecting onabotulinum toxin A (BTA) towards the sphenopalatine ganglion (SPG) using the MultiGuide® in patients with persistent...” PMID 37435807 ↗ Jul 2023 “The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients with certain types of...” NCT00822926 ↗ “The goal of this clinical trial is to learn whether botulinum toxin A (BTA) or autologous nanofat injection is more effective for treating male androgenetic alopecia.” NCT07863856 ↗ “botulinum toxin type A (BTA) is recommended for the treatment of migraine, myofascial pain syndrome, and neuropathic pain accompanied by allodynia.” NCT06470581 ↗ “Recent studies have suggested that intra-articular injection of botulinum toxin A (BTA) may have analgesic effects in degenerative joint diseases.” PMID 29961037 ↗ Jun 2018 “Intradetrusor (bladder) Botulinum toxin A (BTA or Botox®) is a well-established treatment for urinary urgency incontinence (UUI).” NCT05308979 ↗ “stomach injections of botulinum toxin A (BTA), delivered through an endoscope using endoscopic ultrasound (EUS)” NCT00976443 ↗ “IL botulinum toxin type A (BTA) has been postulated in such an indication with controversial reports.” PMID 25810045 ↗ Mar 2015 “Intramuscular injection of botulinum toxin A (BTA) induces reversible flaccid paralysis” NCT06499324 ↗ |
| Known as | BTX | “The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard...” NCT05512039 ↗7“To evaluate the clinical effectiveness of botulinum toxin (BTX) injection into the gastrocnemius muscles in patients with lumbar spinal stenosis (LSS) who have frequent...” PMID 28209505 ↗ Feb 2017 “The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic...” NCT02674269 ↗ “This study examines botulinum toxin (BOTOX, or BTX) for the treatment of muscle twitches and spasticity associated with cerebral palsy in children.” NCT00060957 ↗ “Because of these findings, it has been proposed that a longer-lasting effect could be obtained with the use of OnabotulinumtoxinA (BTX).” NCT05112081 ↗ “patients received from 1 to 4 injections of botulinum toxin with LA (BTX) or LA alone.” PMID 31981833 ↗ Jan 2020 “botulinum toxin A (BTX) would improve rates of primary fascial closure” PMID 26813298 ↗ Feb 2016 “botulinum toxin A (BTX) adds a favourable effect” NCT01590693 ↗ |
| Known as | BTX-A | “Since its introduction in the 1970s for the treatment of strabismus, blepharospasm, and focal dystonia, botulinum toxin type A (BTX-A) has been widely used in the treatment of...” NCT03555916 ↗36“Botulinum toxin A (BTX-A) treatment for glabellar frown lines and crow's feet of a lady who has also periocular vitiligo, we noted gradual and complete resolution of the...” NCT01051687 ↗ “Botulinum Toxin-A (BTX-A) has been increasingly used for the management of bruxism because of its ability to reduce masticatory muscle activity through inhibition of...” NCT07640035 ↗ “Botulinum toxin type A (BTX-A; Botox, Allergan, Inc., Irvine, CA, USA) was administered through intramuscular injection into the masseter and temporalis muscles during a single...” NCT07361900 ↗ “Evidence has been arising suggesting that Botulinum toxin type A (BTX-A) injections can relax smooth muscles fibers in the treatment of obesity and Detrusor muscle over-activity” NCT03355963 ↗ “This study aims to evaluate the effectiveness of onabotulinum toxin A (BTX-A) in patients with MMD who have not responded to conventional non-invasive treatments.” NCT06840730 ↗ “The purpose of the meta-analysis was to evaluate the efficiency of therapeutic botulinum toxin type A (BTX-A) in the prevention of maxillofacial and neck scars.” PMID 26985661 ↗ Mar 2016 “Between 2004 and 2015, a total of 145 patients underwent botulinum toxin-A (BTX-A) injections to treat RP in case reports, retrospective or open studies.” NCT03717961 ↗ “To assess the effect of Botulinum Toxin Type A (BTX-A) injections into the scalene muscles on pain, paresthesias and function in subjects with TOS.” NCT00444886 ↗ “OnabotulinumtoxinA (BTX-A) is an effective treatment for overactive bladder (OAB), but few studies have been done to evaluate injection techniques.” PMID 38484251 ↗ Mar 2024 “Several case reports show potential efficacy of Botulinum Toxin-A (BTX-A) in inducing remission of HS however, these studies are underpowered.” NCT06237465 ↗ |
| Known as | BTX-A-HAC | “Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC; hereafter referred to as BTX-A-HAC Next Generation (BTX-A-HAC NG))” NCT02353871 ↗ |
| Known as | Clostridium Botulinum A Toxin | “Botox (Clostridium Botulinum A Toxin)” NCT01629875 ↗ |
| Known as | DAXI | “DaxibotulinumtoxinA (DAXI), a novel botulinum neurotoxin (BoNT) formulation, was shown to be safe, effective, and long-lasting in the treatment of cervical dystonia (CD) over...” PMID 40439027 ↗ May 20256“This is a randomized, double-blind, placebo-controlled, parallel group, multi-center trial of a single administration of DaxibotulinumtoxinA (DAXI) (high-dose; low-dose) for...” NCT03825315 ↗ “BACKGROUND: SAKURA 3 was a Phase 3, open-label, repeat-dose safety study of DaxibotulinumtoxinA for Injection (DAXI); a component of the largest Phase 3 clinical development...” PMID 32773447 ↗ Jan 2021 “To evaluate the efficacy and safety of daxibotulinumtoxinA-lanm for injection (DAXI) for simultaneous treatment of glabellar, forehead, and lateral canthal (LC) lines.” PMID 36533798 ↗ Nov 2022 “Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)” NCT03786770 ↗ “DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A in clinical development.” PMID 31791824 ↗ Nov 2019 “daxibotulinumtoxinA (DAXI) for injection” NCT02706795 ↗ |
| Known as | DAXI for Injection | “DaxibotulinumtoxinA for Injection (DAXI for Injection)” NCT03911102 ↗ |
| Known as | DaxibotulinumtoxinA | “DaxibotulinumtoxinA (DAXI) for injection is a sterile, lyophilized powder containing 100 units of active daxibotulinumtoxinA per vial, along with inactive ingredients including...” NCT07489430 ↗16“BACKGROUND: SAKURA 3 was a Phase 3, open-label, repeat-dose safety study of DaxibotulinumtoxinA for Injection (DAXI); a component of the largest Phase 3 clinical development...” PMID 32773447 ↗ Jan 2021 “The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.” NCT03137407 ↗ “DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA” NCT03821402 ↗ “DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)” NCT03825315 ↗ “DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A in clinical development.” PMID 31791824 ↗ Nov 2019 “Injectable daxibotulinumtoxinA (RT002) is an investigational botulinum toxin Type A.” PMID 33065952 ↗ Dec 2017 “DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis” NCT02973269 ↗ |
| Known as | DaxibotulinumtoxinA for injection | “DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be...” NCT03608397 ↗ |
| Known as | daxibotulinumtoxinA-lanm | “To evaluate the efficacy and safety of daxibotulinumtoxinA-lanm for injection (DAXI) for simultaneous treatment of glabellar, forehead, and lateral canthal (LC) lines.” PMID 36533798 ↗ Nov 2022 |
| Known as | daxibotuliumtoxinA | “Injectible daxibotuliumtoxinA (DAXI, Revance Therapeutics Inc., Newark, CA) has been shown in large clinical trials to provide safe, effective treatment for glabellar lines and...” NCT05158166 ↗ |
| Known as | DAXXIFY | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06411002 ↗ |
| Known as | DWP-450 (Botulinum purified neurotoxin, Type A) Injection | “DWP-450 (Botulinum purified neurotoxin, Type A) Injection” NCT02334423 ↗1“DWP-450 (Botulinum purified neurotoxin, Type A) Injection” NCT02334436 ↗ |
| Known as | DWP450 | “Botulinum toxin type A(DWP450)” NCT03369990 ↗1“DWP450: Botulinum toxin type A” NCT01945684 ↗ |
| Known as | Dysort | “injection of botulinumtoxinA (AbobotulinumtoxinA /Dysort) into the gastrocnemius (calf) muscle” NCT03978234 ↗ |
| Known as | Dysport | “This prospective double-blind randomized control trial seeks to compare a single formulation of BoNT, aboboutlinum toxin A (Dysport), to a placebo saline group, studying the...” NCT03639766 ↗39“The aim of this study is to prospectively compare the clinical efficacy of Dry Needling (DN), Nabota (PrabotulinumtoxinA), and Dysport (AbobotulinumtoxinA) treatments on the...” NCT07452510 ↗ “Forty patients with stroke with spasticity in a functionally useless arm (median duration 3.1 years) were randomised to receive intramuscular botulinum toxin type A (BT-A;...” PMID 10896696 ↗ Aug 2000 “The aim of this study was to evaluate the efficacy and safety of intramuscular (IM) administration of botulinum toxin type A (Dysport((R)), Ipsen Biopharm Ltd.) for the...” PMID 20359934 ↗ Mar 2010 “This is a 12-week, prospective double-blinded, randomized, multicenter study of placebo, 120 Unit, and 240 unit of botulinum toxin A ( Dysport ® ) injection for patient with a...” NCT00258609 ↗ “The most commonly used subtype is toxin A commercially found as BOTOX (onabotulinumtoxinA, Allergan, approved by FDA in 1989), Dysport (abobotulinumtoxinA, Medicis, approved by...” NCT03186001 ↗ “Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic...” NCT03704155 ↗ “This study aims to evaluate the efficacy of single event multi level chemoneurolysis with the abobotulinumtoxin A drug, Dysport®, on walking energy expenditure and gait in...” NCT03469999 ↗ “In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial;...” NCT03920449 ↗ “The principal aim will be the pain evaluation (Visual Analogue Scale and McGill pain scale) with the use of 200 units of abobotulinumtoxin (Dysport) against placebo in both...” NCT04470401 ↗ “We aimed to compare Dysport (abobotulinumtoxinA, Ipsen Biopharm, Slough, UK) and Botox (onabotulinumtoxinA, Allergan, Irvine, CA, USA) at a 2.5:1 ratio in the treatment of...” PMID 25476727 ↗ Dec 2014 |
| Known as | Dysport (abobotulinumtoxinA) | “Dysport® (abobotulinumtoxinA)” NCT03508869 ↗ |
| Known as | Dysport (abobotulinumtoxinA)injection | “Dysport® (abobotulinumtoxinA)injection” NCT00950664 ↗ |
| Known as | ET-01 | “This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).” NCT04985916 ↗ |
| Known as | GSK1358820 | “GSK1358820 (Botulinum Toxin Type A)” NCT01205451 ↗1“Botulinum toxin A (GSK1358820)” NCT03261167 ↗ |
| Known as | HU-014 | “Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.” NCT05964257 ↗ |
| Known as | HU-045 | “HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short...” NCT06205797 ↗ |
| Known as | iBonT-A | “1 dose of 20 units of incobotulinum toxin A (IBoNT/A) into the glabellar region (GR).” PMID 40434770 ↗ Jul 20251“perineural incobotulinumtoxin-A (iBonT-A) or placebo injections” NCT05623111 ↗ |
| Known as | INA | “IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units.” NCT03571334 ↗ |
| Known as | IncoA | “One-hundred units of Incobotulinumtoxin A (IncoA) or normal saline were injected into tibialis anterior, gastrocnemius, and biceps femoris muscles each side.” PMID 30274305 ↗ Sep 20181“OBJECTIVE: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA)” PMID 28789780 ↗ Aug 2017 |
| Known as | incoBoNT/A | “Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations.” PMID 37205243 ↗ Mar 20231“repeated injections of incobotulinumtoxinA (incoBoNT/A) for treatment of chronic sialorrhea” PMID 34341153 ↗ Oct 2021 |
| Known as | Incobotulinum toxin | “2 ampoules (200 IU) of Incobotulinum toxin , injectable solution presentation 100 IU ampoule” NCT06788158 ↗ |
| Known as | IncobotulinumtoxinA | “The aim of this study is to confirm efficacy and safety of NT 201 (Xeomin®, also known as IncobotulinumtoxinA) after one injection session and to determine the efficacy and...” NCT00541905 ↗80“Neuromuscular retraining therapy and ipsilateral chemodenervation into discoordinated muscles by injection (onabotulinumtoxinA/Botox, Allergan or incobotulinumtoxinA/Xeomin,...” NCT04148872 ↗ “IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of...” NCT01896895 ↗ “The purpose of this study is to assess the patient reported effectiveness of Xeomin (incobotulinumtoxinA) injections into the auricular muscles for relief of tinnitus with use...” NCT05650645 ↗ “This is a double-blind, placebo-controlled study evaluating the safety and efficacy of incobotulinumtoxinA (Merz) for the treatment of provoked vestibulodynia (PVD) associated...” NCT07486830 ↗ “The open-label phase 3 "Treatment with IncobotulinumtoxinA in Movement Open-Label" (TIMO) study investigated longer-term safety and efficacy of incobotulinumtoxin A in...” PMID 34957963 ↗ 2022 “Efficacy and safety of intracavernosal incobotulinumtoxinA (Xeomin) as add-on therapy to sildenafil for the treatment of erectile dysfunction insufficiently responsive to...” PMID 40971935 ↗ Nov 2025 “The authors sought to compare the newest U.S. Food and Drug Administration-approved botulinum toxin type A product, incobotulinumtoxinA, to onabotulinumtoxinA for upper face wrinkles.” PMID 25919246 ↗ May 2015 “Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).” NCT03977493 ↗ “For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected.” NCT05027243 ↗ “Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations.” PMID 37205243 ↗ Mar 2023 |
| Known as | incobotulinumtoxinA (Xeomin) | “incobotulinumtoxinA (Xeomin®)” NCT04970407 ↗1“incobotulinumtoxinA (Xeomin)” NCT02122536 ↗ |
| Known as | MEDITOXIN | “The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy” NCT01256021 ↗1“Botulinum Toxin Type A(Meditoxin®)” NCT01237977 ↗ |
| Known as | Mentor Purified Toxin | “The safety and efficacy of Mentor Purified Toxin, Botulinum Toxin Type A, Purified Neurotoxin, injected intramuscularly into the neck, is being evaluated as a treatment for...” NCT00549341 ↗ |
| Known as | microtoxin | “microdoses of botulinum toxin type A (microtoxin)” NCT07526870 ↗ |
| Known as | Nabota | “ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle” NCT02444351 ↗ |
| Known as | NeurOtoxin | “Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation - The NOVA Study.” PMID 34687654 ↗ Oct 2021 |
| Known as | NT 201 | “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin...” NCT00770211 ↗23“IncobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT01515371 ↗ “incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT00407030 ↗ “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:” NCT00541723 ↗ “Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0.” NCT00430586 ↗ “incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins")” NCT00432666 ↗ “IncobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins")” NCT01603459 ↗ “IncobotulinumtoxinA, also known as NT 201, is a new botulinum toxin type A (150 kDa) that is free from complexing proteins.” PMID 21134045 ↗ Dec 2010 “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins'” NCT00430963 ↗ “NT 201 (IncobotulinumtoxinA/Xeomin®)” NCT00507637 ↗ |
| Known as | OBoNT | “To compare the efficacy and safety of DWP450 with onabotulinumtoxinA (OBoNT) for use in the treatment of glabellar lines, we performed a multicenter, double-blind, randomized,...” PMID 25311357 ↗ Oct 2014 |
| Known as | OBoNT/A | “1 dose of 20 units of onabotulinum toxin A (OBoNT/A);” PMID 40434770 ↗ Jul 2025 |
| Known as | OBTA | “OnabotulinumtoxinA (OBTA) is approved for treating chronic headaches and migraines in adults” PMID 33106278 ↗ Oct 2020 |
| Known as | ONA | “BACKGROUND AND OBJECTIVE: To evaluate the efficacy and safety of onabotulinumtoxinA (ONA) injections to the depressor anguli oris (DAO) to improve downturned mouth.” PMID 36763899 ↗ Feb 20231“Drug: OnabotulinumtoxinA (ONA)” NCT01732809 ↗ |
| Known as | ona-BoNT-A | “Longer waning time is associated with abobotulinumtoxinA (abo-BoNT-A) as compared to onabotulinumtoxinA (ona-BoNT-A)/incobotulinumtoxinA (inco-BoNT-A) formulations.” PMID 37205243 ↗ Mar 2023 |
| Known as | OnaA | “Background: OnabotulinumtoxinA (OnaA) injection in glabella area appears to be a promising treatment for major depression.” PMID 40226647 ↗ Sep 2024 |
| Known as | onabotA | “This 24-week double-blind placebo-controlled multicenter randomized phase 2 trial evaluated efficacy and safety of onabotulinumtoxinA (onabotA; BOTOX) vs. placebo for major...” PMID 31609787 ↗ Jan 20202“botulinum toxin type A (onabotulinumtoxinA; onabotA) injections to induce temporary paralysis in the glabellar muscles” PMID 36849797 ↗ Feb 2023 “onabotulinumtoxinA (onabotA) for moderate or severe PP.” PMID 41933889 ↗ Apr 2026 |
| Known as | onabotulinumtoxin A | “The main objective of this prospective, open, uncontrolled pilot study was to investigate the safety of administering onabotulinumtoxinA (BTA) towards the sphenopalatine...” PMID 34633904 ↗ Oct 2021194“OBJECTIVE: The aim of this multicentre, double-blind, randomized, parallel, active-controlled Phase III clinical trial with two stages (ClinicalTrials.gov identifier:...” PMID 33721365 ↗ Apr 2021 “Treatment consisted of a multimodal approach including intravaginal injections of onabotulinumtoxinA (Botox) and bupivacaine, progressive dilation under conscious sedation,...” PMID 28363809 ↗ Mar 2017 “METHODS: In this Phase 2, randomized, dose-ranging, parallel-group, double-blind, multicenter study, subjects with moderate or severe glabellar lines at maximum frown were...” PMID 28614091 ↗ Nov 2017 “To compare the efficacy and safety of DWP450 with onabotulinumtoxinA (OBoNT) for use in the treatment of glabellar lines, we performed a multicenter, double-blind, randomized,...” PMID 25311357 ↗ Oct 2014 “Neuromuscular retraining therapy and ipsilateral chemodenervation into discoordinated muscles by injection (onabotulinumtoxinA/Botox, Allergan or incobotulinumtoxinA/Xeomin,...” NCT04148872 ↗ “The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard...” NCT05512039 ↗ “The BTX-A group will receive onabotulinumtoxinA (Botox®, Allergan) with mandatory muscles getting 300 units and optional muscles getting up to 100 additional units (maximum...” NCT06296082 ↗ “In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation...” NCT05874154 ↗ “OnabotulinumtoxinA 20 U (10 U per site) or 50 U (25 U per site) were randomly assigned to 150 adults with CAF who were refractory to at least 8 weeks of medical therapy in this...” NCT07543315 ↗ “OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind,...” PMID 22464310 ↗ Mar 2012 |
| Known as | onabotulinumtoxinA (Botox) | “onabotulinumtoxinA (Botox®)” NCT04970407 ↗ |
| Known as | onabotulinumtoxinA neurotoxin | “STUDY QUESTION: Does the depth of injection of onabotulinumtoxinA neurotoxin in the glabellar complex affect efficacy of the BoTN for the improvement of glabellar frown lines?” NCT05766683 ↗ |
| Known as | OnBA | “OBJECTIVE: The aim of this multicentre, double-blind, randomized, parallel, active-controlled Phase III clinical trial with two stages (ClinicalTrials.gov identifier:...” PMID 33721365 ↗ Apr 2021 |
| Known as | onobotulinumtoxinA | “The standard BT injection will be an injection of 25 units of onobotulinumtoxinA (Botox®) diluted in 0.25cc of saline.” NCT03367429 ↗ |
| Known as | onobutilinumtoxinA | “The experimental BT injection will be an injection of 25 units of onobutilinumtoxinA (Botox®) diluted in 0.50cc of saline.” NCT03367429 ↗ |
| Known as | Prosigne | “Prosigne® a new released botulinum toxin serotype A may have the same effectiveness as Botox® in focal dystonia.” PMID 23468866 ↗ Feb 2013 |
| Known as | Refinex | “botulinum toxin type A (Refinex; 5 IU per side)” NCT07715331 ↗ |
| Known as | RT001 | “RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults” NCT01064518 ↗1“RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines” NCT00968825 ↗ |
| Known as | RT002 | “Injectable daxibotulinumtoxinA (an investigational botulinum toxin, RT002) may offer a more prolonged duration of response-and therefore less frequent dosing-than onabotulinumtoxinA.” PMID 30009213 ↗ Apr 20181“Injectable daxibotulinumtoxinA (RT002) is an investigational botulinum toxin Type A.” PMID 33065952 ↗ Dec 2017 |
| Known as | type A botulinum toxin | “Each patient will receive (either in the lower part or the upper part of the scar according to randomization) 50 international units (IU) of type A botulinum toxin (Botox®,...” NCT07013240 ↗ |
| Known as | Vistabel | “A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections” NCT05647551 ↗1“OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units” NCT00777803 ↗ |
| Known as | Xeomeen | “IncobotulinumtoxinA (NT 201, Xeomin/Xeomeen/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany) is a 150-kDa botulinum toxin type A free of complexing proteins.” PMID 23379292 ↗ Feb 2013 |
| Known as | Xeomin | “IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin...” NCT00770211 ↗44“The aim of this study is to confirm efficacy and safety of NT 201 (Xeomin®, also known as IncobotulinumtoxinA) after one injection session and to determine the efficacy and...” NCT00541905 ↗ “IncobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT01515371 ↗ “It consists of a blind injection of 288 IU (/144mL) of BTA (XEOMIN®) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment...” NCT06499324 ↗ “The purpose of this study is to assess the patient reported effectiveness of Xeomin (incobotulinumtoxinA) injections into the auricular muscles for relief of tinnitus with use...” NCT05650645 ↗ “incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum...” NCT00407030 ↗ “Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults...” NCT06205797 ↗ “Botulinum toxin, such as incobotulinumtoxinA (XEOMIN, Merz herapeutics), have been shown to be effective and safe in relaxing these muscles in conditions like spasticity,...” NCT05536570 ↗ “Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).” NCT03977493 ↗ “NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton).” NCT00777803 ↗ “Combination of Xeomin and the ultrasound based delivery system (Vibe) for intravesical administration of the drug in a minimally invasive procedure” NCT06345677 ↗ |
| Action | Inhibit | “Botulinum toxin should be able to inhibit salivary gland secretion by blocking the release of acetylcholine” NCT00173745 ↗ |
| Modality | Protein / enzyme biologic | “Biological: botulinum toxin Type A” NCT00076687 ↗ |
| Route | Other | “BTX injections” NCT00060957 ↗ |
| Target | SNAP25 | “specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25)” NCT02662530 ↗ |